Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US09062X1037
Ticker BIIB
Company BIOGEN
Currency $
Price
Aware Investor Index (AII) 0.8807
Recommendation BUY
P/E 34.31
ROE 15.82 %
Capitalization 68,488,020,000 $
Dividend Yield 0.00 %
P/S 5.58
AII Position 257
P/E Position 484
ROE Position 207
Capitalization Position 127
Dividend Yield Position 596
Sales 12,273,900,000 $
10-Year Average Earnings 1,995,900,000 $
Shares Outstanding 213,000,000
Equity 12,612,800,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
BIOGEN Investor Relations Web Site http://investors.biogen.com/investor-relations







Sales:

YEAR MONTH AMOUNT
2017 12 12,273,900,000.00 $
2016 12 11,448,800,000.00 $
2015 12 10,763,800,000.00 $
2014 12 9,703,300,000.00 $
2013 12 6,932,200,000.00 $
2011 12 5,516,500,000.00 $
2010 12 5,048,600,000.00 $
2009 12 4,716,400,000.00 $
2008 12 4,377,300,000.00 $
2007 12 4,097,500,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,539,100,000.00 $
2016 12 3,702,800,000.00 $
2015 12 3,547,000,000.00 $
2014 12 2,934,800,000.00 $
2013 12 1,862,300,000.00 $
2012 12 1,380,000,000.00 $
2011 12 1,234,400,000.00 $
2010 12 1,005,300,000.00 $
2009 12 970,100,000.00 $
2008 12 783,200,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 12,612,800,000.00 $
2016 12 12,140,000,000.00 $
2015 12 9,372,800,000.00 $
2014 12 10,809,000,000.00 $
2013 12 8,620,200,000.00 $
2012 12 6,961,500,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 213,000,000
2016 12 218,800,000
2015 12 231,200,000
2014 12 237,200,000
2013 12 238,300,000
2012 12 239,700,000

 












Bloomberg News for BIOGEN:



Google News for BIOGEN:

Seeking Alpha - 5 days ago
Biogen 2019 Outlook
Biogen (BIIB) has long been one of the premier biotechnology companies. In the past, most of its income has come from multiple sclerosis ...
WestNewsNow
Biogen (BIIB) Price Target Cut to $375.00
Biogen (NASDAQ:BIIB) had its price objective decreased by equities research analysts at Oppenheimer from $380.00 to $375.00 in a research ...
FDA Headlines
Time To Add Downside Protection To Biogen?
Biogen (BIIB) recently posted its Q4 2018 earnings, yet the stock barely moved. My backtests on the company's earnings movements show this ...
Fairfield Current
Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Data
Shares of Biogen Inc. came under pressure in trading before the U.S. ... oligomers whereas BIIB targets more insoluble aggregated plaque.”.
Fairfield Current - 9 hours ago
As Biogen (BIIB) Valuation Declined, Shareholder Montecito Bank ...
Montecito Bank & Trust decreased its stake in Biogen Inc (BIIB) by 51.05% based on its latest 2018Q3 regulatory filing with the SEC. Montecito ...
The Hi New Ulm
As Biogen (BIIB) Market Value Declined, Holder Saratoga Research ...
Saratoga Research & Investment Management decreased its stake in Biogen Inc (BIIB) by 3.28% based on its latest 2018Q3 regulatory filing ...
PressOracle
Juniper Networks (JNPR) Shareholder Saturna Capital Has ...
Juniper Networks (JNPR) Shareholder Saturna Capital Has Decreased Stake by $397,300; Biogen (BIIB) Holder Johnson Investment Counsel ...
The Yomi Blog (blog)
Biogen down 3% after hours on Mylan patent challenge
Biogen (NASDAQ:BIIB) slips 3% after hours in apparent response to a decision from the USPTO's Patent Trial and Appeal Board allowing an ...
Seeking Alpha - 6 Feb 2019
Mason Street Advisors Stake in Biogen (BIIB) Decreased as Share ...
Mason Street Advisors Llc decreased its stake in Biogen Inc (BIIB) by 4.34% based on its latest 2018Q3 regulatory filing with the SEC. Mason ...
The Hi New Ulm
Biogen Sheds $5 Billion of Value as Drug Challenge Vexes Street
Biogen Inc. shares just posted their biggest one-day plunge since late July as investors weigh the intellectual property risks to the company's ...


Back